On 21 April, a news release from the OECD said that recent seizures of fake medical supplies being marketed as protection against Covid-19 underscore the need to address a growing international trade in counterfeit pharmaceuticals that is costing billions of euros a year and putting lives at risk, according to the OECD and the EU Intellectual Property Office. A joint report says that the trafficking and sale of fake or defective medicines is enriching criminal groups and endangering health while draining away vital industry and tax revenues. Analysis of customs seizures over 2014-16 finds that trade in counterfeit pharmaceuticals was worth €4 billion in 2016. That figure excludes fake medicines produced and consumed domestically and shipments of pharmaceuticals that are stolen in transit and rerouted for sale in a different market or country. The report finds that most of the counterfeit drugs seized over 2014-16 were fake antibiotics, male impotence pills, painkillers and medication for malaria, diabetes, epilepsy, heart disease, HIV/AIDS, cancers, high blood pressure and allergies. Forensic tests of suspect samples show that in 90% of cases, counterfeit medicines can harm patients. More than half the fake medicines seized in recent years originated in India and nearly a third came from China with the main destinations being Africa, Europe and the US. Singapore and Hong Kong are key transit points in the supply chain, with other routes running through the UAE, Egypt, Cameroon and Turkey. Pharmaceutical companies from the US, EU and Switzerland are the hardest hit by counterfeiting.

The report is available at –
http://www.oecd.org/gov/trade-in-counterfeit-pharmaceutical-products-a7c7e054-en.htm
http://www.oecd.org/newsroom/covid-19-crisis-underscores-need-to-address-trade-in-fake-pharmaceuticals-say-oecd-and-euipo.htm
If you’d like to help to contribute to that (badly needed) new laptop or, even better, the new desktop, to replace the one now 5,000 miles away – https://www.buymeacoffee.com/KoIvM842y